HC Wainwright Reiterates Buy Rating for Travere Therapeutics

Analysts maintain positive outlook on biopharmaceutical company's lead product sparsentan

Apr. 14, 2026 at 12:23pm

Got story updates? Submit your updates here. ›

A high-contrast, black and white close-up image of the intricate mechanical components of a pharmaceutical device, conveying the technical sophistication of rare disease therapies.An extreme close-up of the inner workings of a specialized drug delivery system highlights the complex engineering behind rare disease treatments.San Diego Today

Equity research firm HC Wainwright has reiterated its 'buy' rating and $47 price target on shares of Travere Therapeutics (NASDAQ:TVTX), a biopharmaceutical company focused on rare kidney and genetic disorders. The analysts cited the potential of Travere's lead drug candidate sparsentan, which has received accelerated approval from the FDA.

Why it matters

Travere Therapeutics is a key player in the rare disease drug development space, an area that has seen increased investor interest and regulatory support in recent years. The positive rating from HC Wainwright underscores Wall Street's confidence in the company's pipeline and commercial prospects, particularly for sparsentan as a potential treatment for rare kidney diseases.

The details

In its report, HC Wainwright reiterated its 'buy' rating and $47 price target on Travere Therapeutics, implying a potential upside of over 50% from the stock's previous closing price. The analysts cited the company's lead drug candidate sparsentan, which has received accelerated approval from the FDA for the treatment of rare kidney disorders. Travere is currently evaluating sparsentan in late-stage clinical trials for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy, two rare and serious kidney diseases with limited treatment options.

  • Travere Therapeutics stock closed at $30.70 on Tuesday, April 14, 2026.

The players

Travere Therapeutics

A biopharmaceutical company headquartered in San Diego, California, dedicated to developing therapies for rare kidney and genetic disorders.

HC Wainwright

An equity research firm that has reiterated its 'buy' rating and $47 price target on Travere Therapeutics.

sparsentan

Travere's lead drug candidate, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the FDA for the treatment of rare kidney diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We remain positive on Travere Therapeutics and believe sparsentan has significant potential as a treatment for rare kidney disorders.”

— HC Wainwright Analyst

What’s next

Travere Therapeutics is expected to provide updates on the ongoing late-stage clinical trials for sparsentan in the coming months, which could further influence the stock's performance.

The takeaway

Travere Therapeutics' focus on rare disease drug development, particularly with its lead candidate sparsentan, continues to garner positive attention from Wall Street analysts. The reiteration of a 'buy' rating and bullish price target by HC Wainwright underscores the company's promising outlook in the rare disease therapeutics space.